Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Takahisa Kawamura, MD, PhD"'
Autor:
Yasunori Murata, MD, PhD, Shigeru Tanzawa, MD, PhD, Toshihiro Misumi, PhD, Hiroshige Yoshioka, MD, PhD, Eisaku Miyauchi, MD, PhD, Kiichiro Ninomiya, MD, PhD, Masafumi Takeshita, MD, PhD, Kensaku Ito, MD, PhD, Tatsuro Okamoto, MD, PhD, Shunichi Sugawara, MD, PhD, Yosuke Kawashima, MD, Kazuki Hashimoto, MD, Masahide Mori, MD, PhD, Akihiko Miyanaga, MD, PhD, Anna Hayashi, MD, Hisashi Tanaka, MD, PhD, Ryoichi Honda, MD, PhD, Masafumi Nojiri, MD, PhD, Yuki Sato, MD, Akito Hata, MD, Ken Masuda, MD, PhD, Toshiyuki Kozuki, MD, PhD, Takahisa Kawamura, MD, PhD, Takuji Suzuki, MD, PhD, Teppei Yamaguchi, MD, PhD, Kazuhiro Asada, MD, PhD, Satoshi Tetsumoto, MD, PhD, Hiroshi Tanaka, MD, PhD, Satoshi Watanabe, MD, PhD, Yukihiro Umeda, MD, PhD, Kakuhiro Yamaguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Kosuke Tsuruno, MD, PhD, Yuki Misumi, MD, PhD, Hiroshi Kuraishi, MD, PhD, Ken Yoshihara, MD, PhD, Akira Nakao, MD, PhD, Akihito Kubo, MD, PhD, Toshihiko Yokoyama, MD, PhD, Kana Watanabe, MD, PhD, Nobuhiko Seki, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100593- (2023)
Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previou
Externí odkaz:
https://doaj.org/article/0e1d4e104d1e4f01bd75edf40b9e925c
Autor:
Kei Kunimasa, MD, PhD, Motohiro Tamiya, MD, Takako Inoue, MD, Takahisa Kawamura, MD, PhD, Kazumi Nishino, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100442- (2023)
The efficacy of sotorasib for patients with KRAS G12C-mutated lung cancer with poor performance status (PS) and active brain metastases remains unknown. Here, we present a case in which sotorasib was introduced as the third-line therapy for a patient
Externí odkaz:
https://doaj.org/article/6c4f9b81137c4405a6bf4b860c9d8bb6
Autor:
Kei Kunimasa, MD, PhD, Tomohiro Maniwa, MD, PhD, Motohiro Tamiya, MD, Takako Inoue, MD, Takahisa Kawamura, MD, PhD, Jiro Okami, MD, PhD, Kazumi Nishino, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100380- (2022)
Immunochemotherapy is widely used as the primary treatment for advanced lung cancer and is currently being investigated in the perioperative setting. Immunochemotherapy can produce marked tumor shrinkage and long-term anticancer effects that are not
Externí odkaz:
https://doaj.org/article/af29d31283dd4fed9d90dbb7726610e0
Autor:
Takako Inoue, MD, Takahisa Kawamura, MD, PhD, Kei Kunimasa, MD, PhD, Motohiro Tamiya, MD, Hanako Kuhara, MD, PhD, Kazumi Nishino, MD, PhD, Satomi Odani, MPH, Fumio Imamura, MD, PhD, Toru Kumagai, MD, PhD, Kotaro Miyake, MD, PhD, Mihai Dorin Vartolomei.
Publikováno v:
Medicine, Vol 101, Iss 17, p e29076 (2022)
Abstract. Virtual automatic bronchoscopic navigation (VBN) systems to determine the route to peripheral pulmonary lesions (PPLs) in lung cancer can improve diagnostic biopsy yields. However, compared with VBN, drawing manual routes using computed tom
Externí odkaz:
https://doaj.org/article/22a0acdbdab04d0e97a5679d30201c8a
Autor:
Kei Kunimasa, MD, PhD, Takako Inoue, MD, Katsunori Matsueda, MD, Takahisa Kawamura, MD, PhD, Motohiro Tamiya, MD, Kazumi Nishino, MD, PhD, Toru Kumagai, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 2, Pp 100272- (2022)
Effective control of severe immune-related adverse events, including cytokine release syndrome (CRS), is essential for the success of immunotherapy. We present a case of a granulocyte colony-stimulating factor–producing pleomorphic lung carcinoma t
Externí odkaz:
https://doaj.org/article/e483202c5e7d4502b6fdaac83383da21
Autor:
Kei Kunimasa, MD, PhD, Jiro Okami, MD, PhD, Satoshi Takenaka, MD, PhD, Keiichiro Honma, MD, PhD, Yoji Kukita, PhD, Shigenori Nagata, MD, PhD, Takahisa Kawamura, MD, PhD, Takako Inoue, MD, Motohiro Tamiya, MD, Hanako Kuhara, MD, PhD, Kazumi Nishino, MD, PhD, Hideaki Tahara, MD, PhD, Toru Kumagai, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100235- (2021)
A SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rapidly progressing subtype of lung cancer with a poor prognosis and causes early postoperative recurrence among operable patients. In this study, we present a case of SMARCA4-UT with verte
Externí odkaz:
https://doaj.org/article/6fce6fc2448440c289bbd4912081d54c
Autor:
Taichi Miyawaki, MD, Tateaki Naito, MD, PhD, Akihro Kodama, MD, Naoya Nishioka, MD, Eriko Miyawaki, MD, Nobuaki Mamesaya, MD, Takahisa Kawamura, MD, PhD, Haruki Kobayashi, MD, Shota Omori, MD, Kazushige Wakuda, MD, Akira Ono, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Haruyasu Murakami, MD, PhD, Akifumi Notsu, PhD, Keita Mori, PhD, Hideyuki Harada, MD, PhD, Masahiro Endo, MD, PhD, Kazuhisa Takahashi, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100020- (2020)
Introduction: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) i
Externí odkaz:
https://doaj.org/article/b4419d311f174e4794372d4d06ea913f